Skip to main content

Table 1 Patients' characteristics showing AP-2 protein expression

From: Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification

 

AP-2 (α and β isoforms)

AP-2 (α isoform)

Variable

Positive (%)

Negative (%)

χ 2

(P-value)

Positive (%)

Negative (%)

χ 2

(P-value)

Patients age

      

   <40

16

(6.0)

69

(7.6)

2.381 (0.497)

45

(8.7)

35

(8.3)

0.225 (0.973)

   40-50

69 (25.7)

244 (26.9)

 

160 (30.8)

134 (31.7)

 

   51-60

79 (29.5)

285 (31.4)

 

169 (32.6)

133 (31.4)

 

   >60

104 (38.8)

310 (34.1)

 

145 (27.9)

121 (28.6)

 

Primary tumour size

   ≤ 1.5 cm

112 (41.6)

274 (30.3)

12.125 (<0.001)

252

(48.4)

215 (51.6)

0.943

(0.332)

   >1.5 cm

157 (58.4)

631 (69.7)

 

269 (51.6)

202 (48.4)

 

Lymph node Stage

   1

177 (65.8)

554 (61.3)

5.382 (0.068)

331 (63.5)

249 (59.6)

1.949 (0.377)

   2

78

(29.0)

263 (29.1)

 

143 (27.4)

132 (31.6)

 

   3

14

(5.2)

87

(9.6)

 

47

(9.0)

37

(8.8)

 

Grade

   1

60

(22.3)

137 (15.2)

43.672 (<0.001)

66 (12.7)

73

(17.5)

4.476 (0.107)

   2

124 (46.1)

274 (30.3)

 

160 (30.7)

126 (30.2)

 

   3

85

(31.6)

493 (54.5)

 

295 (56.6)

218 (52.3)

 

NPI

   Poor

25

(9.3)

224 (24.8)

35.333 (<0.001)

85

(16.3)

84

(20.1)

3.574

(0.167)

   Moderate

130 (48.3)

517 (57.1)

 

303 (58.2)

219 (52.4)

 

   Good

114 (42.4)

164 (18.1)

 

133 (25.5)

115 (27.5)

 

Development of Distant Metastasis

   No

193 (73.1)

611 (68.0)

2.528 (0.112)

341 (66.1)

302 (71.7)

3.436 (0.064)

   Positive

71

(26.9)

288 (32.0)

 

175 (33.9)

119 (28.3)

 

Development of Recurrence

   No

165 (62.5)

504 (56.4)

3.069 (0.08)

294 (57.8)

248 (60.6)

1.969 (0.374)

   Positive

99

(37.5)

389 (43.6)

 

215 (42.2)

161 (39.4)

 

Vascular invasion

   No

168 (63.2)

495 (55.0)

6.674 (0.036)

286 (55.5)

220 (52.4)

0.949 (0.622)

   Probable

21

(7.9)

109 (12.1)

 

61

(11.8)

52

(12.4)

 

   Definite

77

(28.9)

296 (32.9)

 

168 (32.6)

148 (35.2)

 

Tumour type

   Ductal/NST

129 (49.0)

551 (61.5)

29.22 (<0.001)

326 (63.9)

252 (60.3)

15.31 (0.032)

   Lobular

45

(17.1)

74

(8.3)

 

46

(9.0)

35

(8.4)

 

   Tubular and Tubular mixed

61

(23.2)

178 (19.9)

 

81

(15.9)

90

(21.5)

 

   Medullary

4

(1.5)

29

(3.2)

 

22

(4.3)

7

(1.7)

 

   Other special types*

8

(3.0)

12

(1.3)

 

7

(1.4)

7

(1.7)

 

   Mixed**

16

(6.1)

47

(5.2)

 

26

(5.1)

24

(5.7)

 

Menopausal status

   Premenopausal

103 (38.4)

355 (39.1)

0.038 (0.845)

212 (40.8)

171 (40.4)

0.017 (0.896)

   Postmenopausal

165 (61.6)

553 (60.9)

 

307 (59.2)

252 (59.6)

 
  1. Two different AP-2 antibodies were used; one recognised AP-2α and β isoforms while the other recognised only the AP-2α isoform. *Includes Mucoid, invasive cribriform and invasive papillary carcinoma. **Includes ductal/No special type (NST) mixed with lobular or special types. NPI = Nottingham Prognostic Index.